Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06719934
Starting soon Phase 1

Ttt of Adenomyosis

NCT06719934 · tracked via the Priya Life Science Egypt tracker
Sponsor
Al-Azhar University
Phase
Phase 1
Started
2025-01-01
Last updated
2024-12-06

Condition(s) studied

Adenomyosis

Investigational drug(s) / intervention(s)

Dienogest 2 mg orally →UAE

Dienogest 2 mg orally: 2 mg Dienogest orally

UAE: under local anasthesia uterine artery embolizationwill be done

Study summary

to evaluate use of Dienogest versus uterine arteries embolization in treatment of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms

Eligibility

Sex
FEMALE
Min age
30 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria:- Age Group: 30-50 years * Women with adenomyosis * With or without small fibroids * Suffering from heavy menstrual bleeding, dysmenorrhea, and/or cycle- independent pain and bulk-related symptoms. Exclusion Criteria: * \- Presence of a malignancy or pelvic infection. * An on-going pregnancy or a desire to conceive in the future. * Absolute contraindication for angiography (renal impairment). * Chronic debilitating diseases.

Primary outcome measure(s)

  • evaluation use of Dienogest versus uterine arteries embolization in treatment of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms by questionnaire — through study completion ,an average of 1 year
    evaluation use of Dienogest versus uterine arteries embolization in improvement of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms by questionnaire

Trial sites (1)

FacilityCityRegionStatus
Al Azhar university Asyut Assuit

More Al-Azhar University trials in Egypt

Evaluation of Different Attachments on Implant-Retained Mandibular Overdenture. Recruiting
Impact of Various Acceleration Techniques on En-masse Retraction of Maxillary Anterior Teeth Starting soon
Ultrasound-Guided Microwave Ablation for Breast Fibroadenoma: Safety and Cosmetic Outcomes Starting soon
Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients Starting soon
Artificial Intelligence for the Diagnosis of Gingivitis Active, not recruiting

Other trials for the same condition

Adenomyosis Clinical, Imaging and Histopathology Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06719934 on ClinicalTrials.gov ↗ ← All trials in Egypt